Catalyst Dossier · compiled by CeliA 🧫

LEXICON PHARMACEUTICALS, INC. (LXRX)

Pharmaceutical Preparations · market cap $893M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-15 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-07-15 (est.)Phase 3 · Sotagliflozinimp 9/10
2026-08-05Earningsimp 5/10

Pipeline

Asset	Phase	Indication
LX9211	Phase 2	Diabetic Peripheral Neuropathy
LX4211 Low Dose	Phase 2	Type 2 Diabetes Mellitus
LX3305 low dose	Phase 2	Rheumatoid Arthritis
75 mg LX4211	Phase 2	Type 2 Diabetes Mellitus
250 mg LX1033 tablets	Phase 2	Irritable Bowel Syndrome
Sotagliflozin (SAR439954)	Phase 3	Type 2 Diabetes Mellitus
LX6171 High Dose	Phase 2	Age-Related Memory Disorders
Glimepiride	Phase 3	Type 2 Diabetes Mellitus
Sotagliflozin	Phase 3	Type 2 Diabetes Mellitus
LX7101 (0.125%)	Phase 2	Primary Open-angle Glaucoma
Sulfonylurea	Phase 3	Type 2 Diabetes Mellitus
LX1031 High Dose	Phase 2	Irritable Bowel Syndrome
Telotristat etiprate	Phase 3	Carcinoid Syndrome
Insulin glargine (HOE901)	Phase 3	Type 2 Diabetes Mellitus
LX9211 (blinded)	Phase 2	Diabetic Peripheral Neuropathic Pain

Price & technical context

3-month

+41.5%

6-month

+101.7%

12-month

+157.5%

52-wk range

$0.87–$2.64

vs 50-day MA

+14.7%

vs 200-day MA

+46.8%

Realized vol

85.5%

Max drawdown

-87.8%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for LXRX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 15 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.